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Abstract 
Peripheral arterial disease (PAD), a marker of elevated vascular risk, is highly prevalent in 
general practice. We aimed to investigate patient characteristics and outcomes of PAD 
patients treated according to the guidelines versus those who were not.   
Methods. PACE-PAD was a multicentre, cluster-randomised prospective, longitudinal 
cohort study of patients with PAD in primary care, who were followed-up for death or 
vascular events over 18 months. Guideline-orientation was assumed, if patients received 
anticoagulant/antiplatelet therapy, exercise training, and (if applicable) advice for smoking 
cessation and therapy of diabetes mellitus, hypertension, or hypercholesterolemia, 
respectively.  
Results.  The 5099 PAD patients (mean age 68.0 ± 9.0 years, 68.5% males) who were 
followed-up were in Fontaine stages I, IIa, IIb, III, and IV in 22.5%, 34.6%, 30.1%, 7.8%, 
and 3.5% (1.5%  not specified). Comprehensive guideline orientation was reported in 
28.4% only, however, patients in lower Fontaine stages received more often guideline-
oriented therapy (I: 30.3%; IIa: 31.6%, IIb: 29.1%, III: 9.8%, IV: 18.0%). During 18 
months, 457 patients died (224 due to cerebrovascular or coronary deaths), 319 had instable 
angina pectoris, 116 myocardial infarction, and 140 an ischemic stroke event. In total, 24% 
of patients had experienced any vascular event (19.1% a first event). Event rates did not 
differ between patients treated according to guidelines, and those who were not.  
Conclusion. The present PAD cohort was a high-risk sample with an unexpectedly high rate 
of deaths and vascular events. While physicians appear to focus on the treatment of 
individual risk factors, rates of comprehensive PAD management in line with guideline 
recommendations are still suboptimal. Factors contributing to the lacking difference 
between outcomes in the guideline-oriented and non-guideline-oriented groups may 
comprise low treatment intensity or other reasons for unsatisfactory effect of treatment, 
misclassification of events, patient’s non-compliance with therapy. 
Key words 
Guideline orientation, peripheral arterial disease, outcomes, intermittent claudication, 
observational study. 
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Background 
Substantial advances have been made in the understanding of peripheral arterial disease 
(PAD) and its implications (Belch et al 2003). A series of studies have shown that PAD is 
highly prevalent in the primary care setting and the general population. For example, the 
getABI in 6,880 patients aged at least 65 years found PAD in 21.0% of patients 
[asymptomatic PAD as evidenced by a low ankle-brachial index [ABI] <0.9 in 12.3%, and 
symptomatic PAD in 8.7%] (Diehm et al 2009). The German Heinz Nixdorf Recall Study 
(4814 unselected patients aged 45-75 years) reported PAD in 8.2% in men and 5.5.% in 
women (asymptomatic PAD: 6.4% in men and 5.1% in women) (Kroger et al 2006).   
Further, the increasing awareness of the association of PAD with generalised 
atherosclerosis in other vascular territories has secured its role in primary and secondary 
prevention of cardiovascular disease. PAD patients carry a high risk of premature death, and 
of cardiovascular and cerebrovascular events (Meves et al 2010). According to a recent 
metaanalysis of Heald et al., this risk is doubled, even if all other conventional 
cardiovascular risk factors are accounted for (Heald et al 2006). This is of particular 
importance, as PAD signals a risk higher than - for example - smoking or diabetes mellitus, 
and can therefore guide physicians in selecting patients at particularly high risk. Against the 
background of the high disease burden of PAD associated with increased risk of vascular 
events, an aggressive approach to treat cardiovascular risk factors is recommended in all 
major guidelines, e.g. those of the TransAtlantic Inter-Society Consensus (TASC II) 
(Norgren et al 2007), the American Heart Association (AHA)/ American College of 
Cardiology (ACC) (Hirsch et al 2006) and the newly released joint recommendations of the 
German Society of Angiology (DGA) and other societies.(Deutsche Gesellschaft für 
Angiologie und Gesellschaft für Gefäßmedizin 2009) 
The primary care setting is of particular importance for the management of PAD patients. 
The family physician needs to be efficient in identifying high risk patients, as he serves as a 
gatekeeper for the selection of patients for further assessment or treatment by specialists 
(Grumbach et al 1999), and has a pivotal role in the long-term management of patients 
(Kröger et al 2010).  
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While in other countries the situation of PAD patients in primary care has been repeatedly 
addressed (Hirsch et al 2001, Khan et al 2007), corresponding data from the German 
healthcare system are limited. Against this background, the Patient Care Evaluation - 
Peripheral Arterial Disease (PACE-PAD) Study was initiated. We have previously 
described the baseline results of the study, with focus on the current diagnostics and therapy 
(i.e., management) of patients with newly diagnosed, suspected or confirmed PAD, with 
particular focus on the interaction between general physician and specialist care.(Neumann 
et al 2009) In the present article on the 18-month follow-up, we report (1) the differences of 
patient characteristics and other factors between patients treated according to guidelines and 
those who were not and (2) the outcomes of guideline-oriented therapy on the incidence of 
cardiovascular, cerebrovascular or peripheral vascular events in patients with newly 
diagnosed PAD. 
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Methods 
Design and study flow 
PACE-PAD is a multicentre, cluster-randomised, observational, non-interventional 
prospective longitudinal study, which followed patients with confirmed PAD in stage 
Fontaine I-IV at 3 visits over 18 months (Figure 1). The study was conducted according to 
the principles of “Good Epidemiological Practice (GEP)” (Arbeitsgruppe Epidemiologische 
Methoden der Deutschen Arbeitsgemeinschaft Epidemiologie (DAE)). Protection of patient 
and centre data was ensured. According to a statement of the legal department of the 
University Duisburg-Essen, for this non-interventional study a formal approval was not 
necessary. 
-here insert Figur 1- 
Study course 
Baseline. Patients were eligible for inclusion, if they had suspected symptomatic PAD, i.e., 
newly diagnosed intermittent claudication (IC) or IC-like complaints with PAD suspected 
by the treating physician. Further, patients with suspected asymptomatic PAD were eligible 
for inclusion, if they were aged 55 years or above and had (1) previous myocardial 
infarction and/or (2) previous ischemic stroke and/or (3) manifest type 1 or type 2 diabetes 
mellitus and/or (4) current smoking (for more than 10 years each). If PAD had been 
diagnosed prior to baseline, patients were not eligible for further evaluations (exclusion 
criterion). 
Follow-up/longitudinal study. If the suspicion of PAD was confirmed at the baseline visit, 
patients were followed up for 18 months. Three follow-up visits (F/U 1 at 6 month, F/U 2 at 
12 month, and F/U 3 at 18 month) were scheduled to collect the following information: 
incidence of cardiovascular events (stable or unstable angina pectoris, myocardial infarction 
or coronary revascularisation with or without stenting), cerebrovascular events (stroke or 
transient ischemic attacks [TIA], prolonged ischemic neurological deficit [PRIND], 
revascularisation of the carotids) or peripheral revascularisation or amputation, respectively. 
The longitudinal study endpoints were myocardial infarction, stroke or minor/major 
amputation due to PAD. Further, it was assessed whether patients received guideline-
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 6 
oriented management during follow-up, which was assessed using 6 quality indicators for 
each patient, using a standardised questionnaire (Table 1). The quality indicators were 
defined and assessed by an interdisciplinary board (composed of clinical experts in the 
fields of angiography, cardiology and neurology as well as a methodical specialist regarding 
evidenced based medicine). They comprised prescription of exercise training in the 
Fontaine stages I and II, recommendation of smoking cessation, management of arterial 
hypertension, diabetes mellitus and hypercholesterolemia as well as the use of antiplatelet 
therapy. Guideline-oriented treatment was assumed for example, if a patient with diabetes 
mellitus received dietary measures or at least 1 antidiabetic drug.  
-here insert Table 1- 
Statistics 
The original sample size was calculated based on the assumption that the cumulative 
incidence of vascular events after 18 months was 6.8% in PAD patients with guideline-
oriented therapy versus 9.8% in PAD patients not receiving such therapy. A sample of 
3,483 symptomatic patients (of whom at least 85% were assumed to have diagnosed PAD) 
and of 20,485 patients with risk factors (of whom at least 10% were assumed to have 
diagnosed PAD) was required to obtain a power of 80% at a significance level of 5%. It was 
planned, to test primarily the hypothesis that the cumulative incidence of cardiac, 
cerebrovascular and peripheral vascular events during the follow-up period would be lower 
in PAD patients with guideline-oriented management compared to PAD patients without 
such management. 
Using cross tables, frequency distributions and descriptive statistics, the distributions of 
variables between the two patient strata were compared. In all analyses, a 2-sided- or the 
chi-square p-value <0.05 (to evaluate differences between proportions for two or more than 
two groups) was considered to denote statistical significance. All analyses were performed 
with SPSS Version 15 for Windows (SPSS Inc, Chicago, Ill, USA). 
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Results 
Characteristics. Patients were included by 2,768 physicians. The flowchart in Figure 1 
displays the disposition of patients in the baseline part of the study, and during the 3 follow-
up examinations. Of the 6,129 PAD confirmed patients who were originally included at 
baseline, 22.5% were in Fontaine Stage I, 64.7% in Stage II, 7.8% in Stage III and 3.5% in 
Stage IV (1.5% not specified). In Follow-up 1, 4,645 PAD patients (75.8%), in Follow-up 2 
4,201 patients (68.5%) and in Follow-up 3 3,910 Patients (63.8%) were documented. 
Overall there were 5,099 patients with at least one documented follow-up visit which could 
be included in the analyses. 
-here insert Figure 2- 
Guideline orientation. Only 28.4% of all PAD patients met all applicable (i.e., up to 6) 
quality indicators for guideline-oriented treatment. Nonetheless, the majority of PAD 
patients were to a large extent managed in line with guidelines. Figure 2 shows individual 
quality indicators and the adherence rates over the whole study period of 18 months. With 
exception of exercise training intervention (41.8%), guideline adherence rates with regard to 
the various risk factors were high (82.0% to 92.5%). The great majority of the current 
smokers received the general advice to stop smoking (90.7%). Management of 
hypertension, diabetes mellitus, hypercholesterolemia and antiplatelet therapy in line with 
the respective guidelines, was reported in no less than 88% of the PAD patients each (see 
details in Figure 3). 
-here insert Figure 3- 
Characterisation. Table 2 provides an overview of demographic and clinical patient 
characteristics in the total PAD follow-up cohort, and grouped by guideline-orientation 
status. There were (limited) differences between groups, particularly with regards to mean 
patient age and diabetes status. Mean patient age was slightly lower in the group treated 
according to guidelines compared to the group which was not treated in such a way (66.9 
vs. 68.5 years). Diabetes was more prevalent in the latter group. In contrast the rate of 
patients with previous ischemic events (e. g. myocardial infarctions) and atherothrombotic 
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 8 
manifestations (e.g. angina pectoris) were substantially more frequent in the treatment-
orientation group. 
-here insert table 2- 
 
An analysis by Fontaine status showed that guideline orientation was higher in the early 
PAD disease stages: while in stage I 37.1% of patients were treated according to guidelines, 
in stage III only 9.8% and in stage IV 18.0% were managed accordingly (Table 3). 
-here insert table 3- 
 
Outcomes after 18 months.  During the 18 month follow-up period in the total PAD cohort,  
224 cerebrovascular/coronary deaths, 457 all-cause deaths, 140 ischemic strokes, 116 
myocardial infarctions, 100 minor and 68 major amputations were reported (Fig. 4a). Figure 
4b displays the overall event rates (first event only) at the different follow-up visits. 
Overall, there were 973 events reported during the 18 month follow-up period, 468 at 
Follow-up 1, 280 at Follow-up 2 and 225 at Follow-up 3. 
-here insert figure 4a- 
-here insert figure 4b- 
Table 4a provides an overview of all vascular event rates grouped by guideline-orientation 
status, Table 4b of first event only. There was a statistically significant difference between 
the two subgroups with more overall, cerebrovascular, and peripheral events in the group 
not treated according to guidelines. However, a lower number of vascular deaths (coronary, 
cerebrovascular) and all-cause deaths were reported in this group (Table 4a). 
-here insert table 4a- 
With the exception of follow-up 3, where in the group not treated according to guidelines 
more first events occurred, there was no statistically difference concerning the first event 
(Table 4b). 
-here insert table 4b- 
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Discussion 
While the role of PAD as marker of high risk for cardiovascular disease has been fostered, 
data regarding to actual everyday care of patients with PAD are limited. According to the 
present study, firstly, guideline-oriented therapy which accounts for all major quality 
indicators is the exception rather than the rule. Secondly, unexpected results were noted in 
terms of long-term outcomes with no major differentiation between the subgroups which 
were differentiated by orientation vs. non-orientation to guidelines. 
In the recent years, a number of studies have investigated treatment rates and intensity in 
PAD patients. More than a decade ago, one of the most authoritative studies about the 
treatment situation of PAD patients, PARTNERS, reported relatively low treatment rates in 
1,865 PAD patients (54% on antiplatelets; 56% on lipid lowering drugs; 88% on antihyper-
tensives, 85% on antidiabetics). The “German epidemiological trial on Ankle Brachial 
Index, getABI”, is an ongoing non-interventional study in 6,880 unselected individuals aged 
65 years or older to assess risk factor profile, treatment and prognosis of PAD patients in 
primary care. In the patients with PAD alone assessed at the baseline examination in 2001, 
antiplatelets were prescribed in 53% (versus 65% if coronary or cerebrovascular disease 
was present), lipid-lowering agents in 40.0%, antihypertensives in 93.3%, and antidiabetics 
in 74.4% (Pittrow et al 2003). Further, in the pooled analysis of three large French 
observational studies (ECLAT 1, PRISMA, APRES), patients with PAD alone received 
antiplatelets in 78.9%, lipid-lowering agents in 40.4%, antihypertensives in 25.8%, and 
antidiabetics in 17.0% (Bongard et al 2004). The large contemporary REACH registry 
reported in patients with manifest PAD and the respective concomitant disease or condition, 
drug treatment rates of 92% for hypertension, 86% for diabetes, 70% for hyperlipidemia, 
and 82% for antiplatelet use (Bhatt et al 2006). While at first glance these rates appear 
satisfactory, in that registry only a minority of patients were at target goals for blood 
pressure, glucose, cholesterol, body weight and non-use of tobacco (Bhatt, Steg 2006).  
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Notably, in all reported studies, treatment intensity was dependent on comorbidity: if in 
addition to PAD, coronary heart disease or cerebrovascular disease was concomitantly 
present, treatment rates had consistently improved. 
It should be noted that current treatment recommendations for PAD patients are based on 
various strength of evidence. The recommendation for smoking cessation (counselling, 
nicotine replacement, bupropion) is based on evidence level I B (consistent evidence, based 
on a single randomised or on non-randomised studies), for physical exercise on IA (several 
randomised studies or metaanalyses available). In contrast, the evidence is considered to be 
weaker for lipid lowering (level II B), and diabetes treatment (II C). While the evidence for 
the use of antiplatelet drugs is strong (I A), it should be noted that the underlying data are 
based on symptomatic patients. While antiplatelet therapy has been recommended in 
diabetic patients and/or PAD patients (American Diabetes Association 2003, American 
Diabetes Association 2007), the recent results of the POPADAD study in patients with 
diabetes and concomitant asymptomatic PAD did not provide evidence to support the use of 
ASS or antioxidants in primary prevention of cardiovascular events and mortality.(Belch et 
al 2008)  Similarly, in the large Japanese JPAD study, primary prevention in diabetic 
patients with low dose acetylic salicylic therapy did not reduce vascular event rates (Ogawa 
et al 2008).  Very recently, Fowkes et al reported the results of the AAA study: Among 
participants without clinical cardiovascular disease, identified with a low ABI based on 
screening a general population, the administration of acetylic salicylic acid compared with 
placebo did not result in a significant reduction in vascular events (Fowkes et al 2010). 
Other reasons beyond the varying strength of evidence may account for the reluctance of 
physicians to adhere to the PAD guidelines. Basically, many physicians still underestimate 
the importance of PAD in relation to CHD or CVD (Belch, Topol 2003). Second, the 
expectation in the management of younger patients that life style change or other non-
pharmacological treatment may be sufficient (Pickering 2003), and in elderly the fear of 
doing harm by applying too-intensive treatment for example with regards to 
antihypertensive therapy (Berlowitz et al 1998, Chobanian 2001) accounts for 
undertreatment. Further, the high number of guidelines in various fields, and their length 
and complexity makes it difficult for the physician to keep abreast with the plethora of 
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information. Clinical inertia on the side of physicians might be the result. (Phillips et al 
2001) 
With respect to outcomes at 1.5 years, in our study the total incidence of deaths and 
vascular events was 23.5%, an unexpectedly high rate, which hints at the inclusion of 
patients with advanced disease (or multiple risk factors). For comparison, in PAD patients 
the 1-year incidences of death plus major vascular events were 8.3% in getABI (Lange et al 
2005)  and 5.4% in REACH (Steg et al 2007). 
For our investigation, we chose a real-life, non-interventional study design in order to 
obtain data on actual practice patterns. This ensured that various types of PAD patients with 
a broad variety of concomitant diseases or medications could be investigated. However, 
when interpreting the results of the present study, several limitations have to be taken into 
account. First, the study was observational and not randomised, which means that unknown 
biases cannot be ruled out.(Benson et al 2000, Sinatra et al 2005) While physicians were 
requested to document eligible patients consecutively, there was no additional log-file of all 
patients in the practice to exclude possible selection processes. Further, no data are 
available about those patients who could not be followed up. The rate of lost-to-follow-up 
patients was substantial (about a quarter), and it can be hypothesized that these patients are 
less well treated than more compliant patients. No information was collected on reasons 
why guideline-oriented treatment was not pursued (example: contraindication to exercise 
training in patients with musculoskeletal disease or due to acute cold). The missing 
difference between outcomes in the guideline-oriented and non-guideline-oriented groups 
may be due to various factors, which comprise low treatment intensity and therefore 
unsatisfactory clinical effect, underestimation of the implications of PAD (Hirsch et al 
2007) with resulting patient non-compliance or non-adherence with therapy. Further, a lack 
of effect in certain subgroups, e.g. missing effect of antithrombotic therapy in the 
asymptomatic patients as noted in the AAA study(Fowkes, Price 2010), or in the high 
Fontaine stages, might account for the non-differentiation. Finally, methodological issues 
cannot be fully excluded, such as misclassification of events. 
 
Conclusions 
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The present PAD cohort was a high-risk sample with an unexpectedly high rate of deaths 
and vascular events. The proportion of patients treated comprehensively according to the 
guidelines was relatively low, which calls for an optimisation. There was a lack of 
differentiation between the guideline-oriented on non-guideline oriented therapy in terms of 
outcomes, which may be due to patient-related or other factors, and calls for further 
research. 
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Figure 1. Flow chart with disposition of patients  
 
All patients
N=12.052
Group A
2.131 patients
Group B
9.921 patients
6.129 PAD patients
Follow-up I Available N=4.645 patients 
(75,8%)
Unincluded patients:
- Missings: 947
- Removed: 80
- died: 173
- Change of physican: 284
Follow-up II Available N=4.201 patients 
(68,5%)
Unincluded patients:
- Missings: 1.139
- Removed: 90
- died: 145
- Change of physican: 301
Follow-up III Available N=3.910 patients 
(63,8%)
Unincluded patients:
- Missings: 415
- Removed: 53
- died: 139
- Change of physican: 200
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Figure 2. Guideline orientation, by individual quality indicators   
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Figure 3. Quantification of guideline orientation, by individual quality indicators over 
time 
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Figure 4a. Outcomes at 18 months (all-cause death and vascular events) 
 
 
 
Figure 4b. Outcomes at 18 months (first event) 
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Table 1. Guideline-oriented therapy: definitions of quality indicators  
 
Item Definition Specification for Fontaine stage 
 
Anticoagulant/antiplatelet therapy Prescription of at least 1 drug   II -IV 
If present: smoking  Cessation advice, if applicable All stages 
Exercise training  Prescription or recommendation  of regular training  I and II only 
If present: diabetes mellitus Dietary measure or at least 1 antidiabetic drug All stages 
If present: hypercholesterolemia Dietary measure or at least 1 lipid lowering drug II - IV  
If present: hypertension Dietary measure or at least 1 antihypertensive drug  All stages 
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Table 2. Fontaine stages in the total cohort, and by overall guideline orientation status   
 
  All PAD patients   PAD treated 
according to 
guidelines 
PAD not treated 
according to 
guidelines  
Comparison between 
PAD subgroups  
(p value)  
 %  (N) %  (n) %  (n)  
All patients  100 (5099) 28.4 (1450)  71.6 (3649)  
 
Fontaine stages      
I (asymptomatic) 100  (1145) 30.3   (347) 69.7  (798) 0.115 
IIa (mild claudication) 100  (1765) 31.6  (557) 68.4 (1208) <0.05 
IIb (moderate to severe 
claudication) 
100  (1534) 29.1  (446) 70.9 (1088) 0.521 
III (ischemic rest pain) 100  (399)                        9.8    (39) 90.2  (360) <0.05 
IV (ulceration or gangrene) 100  (178) 18.0  (32) 82.0  (146) <0.05 
Missing/multiple stages 100      (78) 37.2   (29) 62.8     (49) <0.05 
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Table 3. Patient characteristics overall and by guideline-orientation 
Parameter All PAD patients  
 
 
(N=5099)  
PAD treated 
according to 
guidelines 
(n=1450) 
PAD not treated 
according to 
guidelines 
(n= 3649)  
Comparison 
between subgroups 
(p value)  
Age (years), mean ± SD 
< 65 years, % 
≥ 65 years, % 
 
68.0+-9.0 
36.2 
63.8 
66.9 ± 8 
41.2   
58.8  
               68.5± 9 
34.2  
65.8  
<0.05 
<0,05 
<0,05 
Males: females,  % 68.5:31.5 72.8:27.2 66.8:33.2 <0.05 
Body Mass Index (kg/m
2
) 27.7 27.8 27.7   0.33 
Systolic and diastolic BP, mean 
(mmHg) 
140.4/82.1 140.0/82.3 140.5/81.9 0.34; 0.15 
Complaints (intermittent 
claudication), % 
85.7 85.6 85.7  0.89 
Vascular risk factors     
None/1/2/3/4, n 320/2.427/1.815/48
7/50 
90/736/560/151/
15 
230/1.691/1.255/336/
35 
 0.90 
Current Smoking,   53.2 (2711) 52.0 (807) 53.7 (1904)  0.27 
 > 10 years 94.6 (2565) 93.9 (758) 94.9 (1807)   0.17 
Diabetes mellitus     54.9 (2801) 52.0 (807) 56.2 (1994) <0.05 
 > 10 years 74.6 (2091) 76.9 (621) 73.7 (1470) <0.05 
Arterial hypertension     76.0 (3877) 77.3 (1199) 75.5 (2678)  0.19 
 > 10 years 70.3 (2727) 69.8 (837) 70.6 (1890)   0.33 
Hypercholesterolemia    69.4 (3537) 70.6 (1096) 68.8 (2441)  0.21 
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 > 10 years 58.9 (2082) 60.4 (662) 58.2 (1.420)   0.11 
Carotid stenosis,      11.1 (567) 11.7 (182) 10.9 (385)  0.36 
Ischemic events in history 
(prior to baseline) 
    
None/1/2/3/4/5/missing 44.4/23.0/21.8/8.2/
2.3/0.3 
40.1/23.1/24.7/9.
2/2.6/0.5 
46.3/22.9/20.6/7.7/2.
1/0.4 
<0.05 
Cerebrovascular: any      23.4 (1.191) 23.9 (371) 23.1 (820)  0.54 
TIA/PRIND      15.9 (812) 16.8 (260) 15.6 (552)  0.30 
Ischemic Stroke     16.5 (840) 16.2 (252) 16.6 (588)  0.78 
Coronary: any    43.0 (2192) 48.1 (746) 40.8 (1446) <0.05 
Stable AP      33.1 (1688) 36.0 (558) 31.9 (1130) <0.05 
Unstable AP      9.6 (488) 11.0 (170) 9.0 (318) <0.05 
Myocardial infarction, 26.8 (1366) 32.4 (503) 24.3 (863) <0.05 
 
Values indicate % (n), if not specified otherwise. AP, angina pectoris; TIA, transient ischemic attack;  
PRIND, prolonged reversible ischemic neurological deficit 
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Table 4a. Vascular events during the 18-month follow-up (F/U 1 to 3, all events) 
Parameter All PAD 
patients  
 
(N=5099)  
PAD treated 
according to 
guidelines  
(n=1450) 
PAD not treated 
according to 
guidelines 
(n= 3649)   
Comparison 
between 
subgroups  
(p value)  
 % (n)  % (n)  % (n)  
Coronary 8.6 (435)  8.2 (119)  8.7 (316)    0.25 
Cerebrovascular 2.7 (140) 2.1 (30)  3.0 (110)  <0.05 
Peripheral 3.3 (168)  1.5 (22)  4.0 (146)  <0.05 
Deaths (coronary, cerebrovascular) 4.4 (224)  5.8 (84)  3.8 (140)  <0.05 
Deaths (all) 9.0 (457)  12.4 (180)  7.6 (277)  <0.05 
Overall 23.5 (1200)  24.2 (351)  23.3 (849)  <0.05 
Table 4b. Vascular events during the 18-month follow-up period (first event) 
Parameter All PAD patients 
(N=5099)  
PAD treated 
according to 
guidelines 
PAD not treated 
according to 
guidelines  
Comparison 
between 
subgroups  
(p value)  
 % (n) % (n)  % (n)  
FU1 9.2 (468)  10.3 (160)  8.7 (308)     0.07 
FU2 5.5 (280)  5.8 (90)  5.4 (190)     0.55 
FU3 4.4 (225)  3.4 (52)  4.8 (173)  <0.05 
Overall 19.1 (973)  19.5 (302)  18.9 (671)     0.67 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 28 
 
 1 
Outcomes of medical management of peripheral arterial 
disease in general practice: follow-up results of the 
PACE-PAD Study 
  
Anja Neumann (1), Rebecca Jahn (1), Curt Diehm (2), Elke Driller (3), Franz Hessel (1), 
Gerald Lux (1), Oliver Ommen (3), Holger Pfaff (3), Uwe Siebert (4), David Pittrow (5), 
Jürgen Wasem (1), on behalf of the Patient Care Evaluation - Peripheral Arterial Disease 
(PACE-PAD) Study Investigators* 
  
(1) Alfred Krupp von Bohlen und Halbach-Stiftungslehrstuhl für Medizin-Management, 
Universität Duisburg-Essen, Germany 
(2) Klinikum Karlsbad Langensteinbach, Karlsbad 
(3) Zentrum für Versorgungsforschung, Universität zu Köln, Germany 
(4) Department of Public Health, Medical Decision Making and Health Technology 
Assessment, University for Health Sciences, Medical Informatics and Technology (UMIT), 
Hall, Austria 
(5) Institute for Clinical Pharmacology, Medical Faculty Carl Gustav Carus, Technical 
University Dresden, Germany 
 
Correspondence:  
Prof. Dr. rer. pol. Jürgen Wasem, Universität Duisburg-Essen, Alfried Krupp von Bohlen 
und Halbach-Stiftungslehrstuhl für Medizin-Management, Schützenbahn 70, D-45127 
Essen; Tel.: +49 (0)201-183-4072 , Fax +49 (0)201-183-4073; E-Mail: anja.neumann@uni-
due.de oder pace-pad@uni-due.de 
 
*The study group was supported by an advisory board founded in 2003 with the following 
members: Hans Jürgen Ahrens, Curt Diehm, Leonhard Hansen (until 2004), Klaus-Dieter 
Kossow.  
*Title Page
